Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: The Losartan Intervention for Endpoint (LIFE) Reduction in Hypertension Study Academic Article uri icon

Overview

MeSH Major

  • Antihypertensive Agents
  • Diabetes Mellitus
  • Hypertrophy, Left Ventricular

abstract

  • Hypertensive patients with diabetes have less regression of CP LVH in response to antihypertensive therapy than patients without diabetes, and regression of ECG LVH is less useful as a surrogate marker of outcomes in hypertensive patients with diabetes. These findings may in part explain the higher CV morbidity and mortality in hypertensive patients with diabetes, and the absence of a demonstrable improvement in prognosis in diabetic patients in response to regression of ECG LVH suggests a more complex interrelation between underlying LV structural and functional abnormalities and outcome in these patients.

publication date

  • March 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.105.574822

PubMed ID

  • 16534012

Additional Document Info

start page

  • 1588

end page

  • 96

volume

  • 113

number

  • 12